Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial.

Date publication

février 2017

Journal

The Lancet. Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr KLEINCLAUSS François

Tous les auteurs :
Azzouzi AR, Vincendeau S, Barret E, Cicco A, Kleinclauss F, van der Poel HG, Stief CG, Rassweiler J, Salomon G, Solsona E, Alcaraz A, Tammela TT, Rosario DJ, Gomez-Veiga F, Ahlgren G, Benzaghou F, Gaillac B, Amzal B, Debruyne FM, Fromont G, Gratzke C, Emberton M,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/28007457

Résumé

Vascular-targeted photodynamic therapy, a novel tissue-preserving treatment for low-risk prostate cancer, has shown favourable safety and efficacy results in single-arm phase 1 and 2 studies. We compared this treatment with the standard of care, active surveillance, in men with low-risk prostate cancer in a phase 3 trial.

Mots clés

Adult, Aged, Aged, 80 and over, Bacteriochlorophylls, therapeutic use, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Grading, Neoplasm Staging, Photochemotherapy, Photosensitizing Agents, therapeutic use, Population Surveillance, Prognosis, Prostatic Neoplasms, drug therapy, Risk Assessment, Survival Rate

Référence

Lancet Oncol.. 2017 Feb;18(2):181-191